Correlation Between Royalty Management and Artiva Biotherapeutics,
Can any of the company-specific risk be diversified away by investing in both Royalty Management and Artiva Biotherapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Royalty Management and Artiva Biotherapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Royalty Management Holding and Artiva Biotherapeutics, Common, you can compare the effects of market volatilities on Royalty Management and Artiva Biotherapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Royalty Management with a short position of Artiva Biotherapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Royalty Management and Artiva Biotherapeutics,.
Diversification Opportunities for Royalty Management and Artiva Biotherapeutics,
-0.54 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Royalty and Artiva is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Royalty Management Holding and Artiva Biotherapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Artiva Biotherapeutics, and Royalty Management is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Royalty Management Holding are associated (or correlated) with Artiva Biotherapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Artiva Biotherapeutics, has no effect on the direction of Royalty Management i.e., Royalty Management and Artiva Biotherapeutics, go up and down completely randomly.
Pair Corralation between Royalty Management and Artiva Biotherapeutics,
Given the investment horizon of 90 days Royalty Management Holding is expected to generate 0.87 times more return on investment than Artiva Biotherapeutics,. However, Royalty Management Holding is 1.15 times less risky than Artiva Biotherapeutics,. It trades about 0.01 of its potential returns per unit of risk. Artiva Biotherapeutics, Common is currently generating about -0.05 per unit of risk. If you would invest 130.00 in Royalty Management Holding on December 8, 2024 and sell it today you would lose (29.50) from holding Royalty Management Holding or give up 22.69% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 64.37% |
| Values | Daily Returns |
Royalty Management Holding vs. Artiva Biotherapeutics, Common
Performance |
| Timeline |
| Royalty Management |
| Artiva Biotherapeutics, |
Royalty Management and Artiva Biotherapeutics, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Royalty Management and Artiva Biotherapeutics,
The main advantage of trading using opposite Royalty Management and Artiva Biotherapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Royalty Management position performs unexpectedly, Artiva Biotherapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Artiva Biotherapeutics, will offset losses from the drop in Artiva Biotherapeutics,'s long position.| Royalty Management vs. Arm Holdings plc | Royalty Management vs. Globalfoundries | Royalty Management vs. Black Spade Acquisition | Royalty Management vs. ASE Industrial Holding |
| Artiva Biotherapeutics, vs. United Guardian | Artiva Biotherapeutics, vs. Analog Devices | Artiva Biotherapeutics, vs. ServiceNow | Artiva Biotherapeutics, vs. FARO Technologies |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Complementary Tools
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |